PALO ALTO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. announced that it has cancelled its corporate presentation planned for today at the Lazard Capital Markets 5th Annual Healthcare Conference due to the proximity of the release of preliminary top-line data from the first Phase III pivotal clinical trial of JZP-6 (sodium oxybate) for the treatment of fibromyalgia.
The company anticipates that it will release the preliminary top-line data within the next week.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995
This press release contains a forward-looking statement related to the timing of the release of clinical results related to Jazz Pharmaceuticals’ JZP-6 product candidate for the treatment of fibromyalgia. This forward-looking statement is based on the company’s current expectations and inherently involves significant risks and uncertainties. The actual timing of the release of clinical results could differ from that anticipated in such forward-looking statement as a result of these risks and uncertainties. Risk factors related to Jazz Pharmaceuticals’ clinical trials are discussed under “Risk Factors” in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 14, 2008.
CONTACT: Karen L. Bergman, +1-650-575-1509, or Michelle Corral,
+1-415-794-8662, both of BCC Partners for Jazz Pharmaceuticals, Inc.
Web site: http://www.jazzpharmaceuticals.com/
